No effect of scalp cooling on survival among women with breast cancer
- 550 Downloads
Scalp cooling can prevent chemotherapy-induced alopecia in some cancer patients. It is not used in all countries. No data are available regarding its impact, if any, on survival. The aim of this study was to compare overall survival according to whether or not scalp cooling was used during neoadjuvant or adjuvant chemotherapy for non-metastatic breast cancer. We conducted a retrospective cohort study of 1,370 women with non-metastatic invasive breast carcinoma who received chemotherapy in the neoadjuvant or adjuvant setting. A total of 553 women who used scalp cooling came from a tertiary breast cancer clinic in Quebec City (diagnosed between 1998 and 2002) and 817 were treated in other hospitals in the province of Quebec (between 1998 and 2003) where scalp cooling was not routinely available. Overall survival of women who used scalp cooling and those who did not was compared using Cox proportional hazards models. Median follow-up for the scalp-cooled and the non-scalp-cooled groups was 6.3 years and 8.0 years, respectively. Overall mortality was no different (adjusted hazard ratio 0.89, 95 % confidence interval: 0.68–1.17, p = 0.40) among scalp-cooled women, compared to those not getting scalp cooling. Among women getting neoadjuvant or adjuvant chemotherapy for non-metastatic breast cancer, scalp cooling used to prevent chemotherapy-induced alopecia had no negative effect on survival. To our knowledge, this is the first study to compare survival of women who used scalp cooling to that of women who did not.
KeywordsBreast cancer Scalp cooling Survival Alopecia
J.L. was a Clinical Research Scholar from the Fonds de Recherche en Santé du Québec (FRQS) at the time of this work.
Conflict of interest
The authors declare that they have no conflicts of interest.
The study is a chart review and scalp cooling use was routine at the CMSDF.
- 3.Sedlacek SM (2006) Persistent significant alopecia (PSA) from adjuvant docetaxel after doxorubicin/cyclophosphamide (AC) chemotherapy in women with breast cancer. Breast Cancer Res Treat 100:s116–s116 Abstract No 2105Google Scholar
- 6.van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JW, Breed WP (2012) Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta Oncol 51(4):497–504. doi: 10.3109/0284186X.2012.658966 PubMedCrossRefGoogle Scholar
- 11.Perron L, Major D, Hébert-Croteau N, Brisson J (2011) Évolution de la détection précoce, l’investigation, le traitement et la survie chez les femmes avec un cancer du sein diagnostiqué entre 1993 et 2003 au Québec, 2011th edn. Institut national de santé publique du Québec, QuébecGoogle Scholar
- 12.Cox D (1972) Regression models and life tables. J Stat Soc 34:187–220Google Scholar
- 13.Gooiker GA, van Gijn W, Post PN, van de Velde CJ, Tollenaar RA, Wouters MW (2010) A systematic review and meta-analysis of the volume-outcome relationship in the surgical treatment of breast cancer. Are breast cancer patients better of with a high volume provider? Eur J Surg Oncol 36:S27–S35PubMedCrossRefGoogle Scholar
- 15.El-Saka RO, El-Husseiny, G., Rostom, Y., Salama, A., (2009) Scalp cooler efficacy to reduce anthracycline-induced alopecia and its QOL impact in breast cancer. In: ASCO, 2009Google Scholar